Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.52 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27597539 | 0.91 | ESR1 (0.50) | ESR1ESR2ABATBLMCA2 | |
| Trifluoroacetic Acid SCHEMBL30392295 | 0.87 | BLM (0.55) | ESR1ESR2BLMCA2ALDH1A1 | |
| SCHEMBL7670360 | 0.86 | ESR1 (0.38) | ESR1ESR2ALDH1A1SLC6A2CYP2C19 | |
| SCHEMBL27537002 | 0.85 | ESR1 (0.61) | ESR1ESR2BLMALDH1A1SLC6A2 | |
| SCHEMBL11467045 | 0.84 | ESR1 (0.48) | ESR1ESR2ABATBLM | |
| SCHEMBL15535667 | 0.79 | TSHR (0.43) | ESR1CA2CA12CA1CA4 | |
| SCHEMBL25596195 | 0.77 | BLM (0.63) | ESR1ESR2ABATBLMCA2 | |
| SCHEMBL25596196 | 0.77 | BLM (0.63) | ESR1ESR2ABATBLMCA2 | |
| SCHEMBL10570 | 0.76 | ALDH1A1 (0.52) | KDM4EALDH1A1TAAR1MEN1CYP3A4 | |
| SCHEMBL7109436 | 0.76 | ESR1 (0.61) | ESR1ESR2ABATBLMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111087650-B | Vulcanizing agent system for fluororubber, fluororubber compound and application | 浙江加诚新材料有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-111087650-A | Vulcanizing agent system for fluororubber, fluororubber compound and application | 浙江加诚新材料有限公司 | 2020-05-01 | — | — | CN | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4384503-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023018781-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018781-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0091512-B1 | 6-FLUORO-3-(3-(1-HETEROCYCLO)PROPYL)-1,2-BENZISOXAZOLES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4598152-A | ANTIPSYCHOTICS, HYPOTENSIVE AGENTS, ANALGESICS | HOECHST-ROUSSEL PHARMACUETICALS INC. (US) | 1986-07-01 | — | — | US | disclosed |
| US-4591586-A | ANALGESICS, HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1986-05-27 | — | — | US | disclosed |
| US-4524209-A | TREATMENT OF PSYCHOSIS AND ALLEVIATION OF PAIN | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-06-18 | — | — | US | disclosed |
| US-4458075-A | ANALGESICS, ANTIPSYCHOTICS, HYPOTENSIVES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | ESR1 1212/4885ESR2 884/4885ABAT 3289/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | ESR1 1106/4885ESR2 1201/4885ABAT 3600/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | ESR1 3756/4885ESR2 4069/4885ABAT 1644/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | ESR1 3403/4885ESR2 2432/4885ABAT 814/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ESR1 1106/4885ESR2 1201/4885ABAT 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.